DPP4 and Miyoshi myopathy: In the 9 male MM cases treated with Q2W administration, no significant difference was observed in variation between serum sCD26/DPP4 titer and tumor volume, although there was a trend for a correlation between pre/post day 29 serum sCD26/DPP4 titer and PFS (Additional file 8 (Table S7)).